This HTML5 document contains 52 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n11http://linked.opendata.cz/resource/drugbank/mixture/
n9http://linked.opendata.cz/resource/drugbank/drug/DB08936/identifier/chebi/
n6http://bio2rdf.org/drugbank:
n12http://linked.opendata.cz/resource/drugbank/drug/DB08936/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n10http://linked.opendata.cz/resource/drugbank/drug/DB08936/identifier/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://www.drugs.com/international/
n16http://linked.opendata.cz/resource/atc/
n15http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB08936
rdf:type
n3:Drug
n3:description
Chlorcyclizine is a first generation phenylpiperazine class antihistamine used to treat urticaria, rhinitis, pruritus, and other allergy symptoms. Chlorcyclizine also has some local anesthetic, anticholinergic, and antiserotonergic properties, and can be used as an antiemetic.
n3:generalReferences
# Enright BP, Gu YZ, Snyder RD, Dugyala RR, Obert LA, Treinen KA, McIntyre BS, Veneziale RW: Effects of the histamine H1 antagonist chlorcyclizine on rat fetal palate development. Birth Defects Res B Dev Reprod Toxicol. 2010 Dec;89(6):474-84. doi: 10.1002/bdrb.20261. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/21058326 # http://www.medicinescomplete.com/mc/clarke/current/CLK0327.htm # KUNTZMAN R, KLUTCH A, TSAI I, BURNS JJ: PHYSIOLOGICAL DISTRIBUTION AND METABOLIC INACTIVATION OF CHLORCYCLIZINE AND CYCLIZINE. J Pharmacol Exp Ther. 1965 Jul;149:29-35. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14334288
n3:group
approved
n3:halfLife
about 12 h.
owl:sameAs
n6:DB08936
dcterms:title
Chlorcyclizine
adms:identifier
n9:127544 n10:DB08936 n12:Chlorcyclizine
n3:routeOfElimination
Slowly excreted in the urine; measurable amounts of norchlorcyclizine have been detected in the urine for up to 3 weeks after the cessation of chronic oral administration. About 0.5% of a single dose is excreted in the urine as the N-oxide.
n3:synonym
Chlorcyclizine Chlorcyclizinum Clorciclizina Chlorcyclizin
n3:volumeOfDistribution
After a single oral dose of 2 mg/kg to 4 subjects, average peak plasma concentrations of about 0.05 mg/L and 0.03 mg/L were attained in 5 h for unchanged drug and norchlorcyclizine, respectively. After oral administration of 50 mg 3 times a day for 6 days, plasma concentrations of norchlorcyclizine of 0.05 to 0.11 mg/L were reported on the first day after the cessation of treatment and plasma concentrations of 0.02 to 0.04 mg/L were found on the 10th day after cessation of treatment [Kuntzman et al. 1973].
n3:mixture
n11:271B5E12-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
about 85 to 90%.
n3:salt
n3:synthesisReference
Baltzly, R. and Castillo, J.C.; U.S. Patent 2,630,435; March 3, 1953; assigned to Burroughs- Wellcome & Co. (USA.) Inc.
foaf:page
n14:chlorcyclizine.html
n3:IUPAC-Name
n4:271B5E17-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5E1D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5E1C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5E19-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5E1A-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5E1B-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5E15-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5E13-363D-11E5-9242-09173F13E4C5 n4:271B5E16-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5E14-363D-11E5-9242-09173F13E4C5
n15:hasATCCode
n16:R06AE04
n3:H-Bond-Acceptor-Count
n4:271B5E23-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5E24-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5E1E-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5E1F-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5E21-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5E20-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5E22-363D-11E5-9242-09173F13E4C5
n3:absorption
Readily absorbed after oral administration and widely distributed throughout the body. Metabolised by N-demethylation to form norchlorcyclizine and by N-oxidation.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
82-93-9
n3:category
n3:Bioavailability
n4:271B5E28-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5E2A-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5E2B-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5E2C-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5E27-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5E26-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5E29-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5E18-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5E25-363D-11E5-9242-09173F13E4C5